AustinPx | LinkedIn (original) (raw)

Pharmaceutical Manufacturing

Georgetown, TX 2,862 followers

Client-Centric CDMO helping developers realize the full potential of their drug candidates.

View all 46 employees

About us

AustinPx™, Pharmaceutics and Manufacturing, was founded to help developers realize the full potential of their drug candidates. There are many obstacles to bringing a drug to market, including poor bioavailability and accelerated timelines. That’s where we come in. Our client-centric approach is designed to simplify the complexity of outsourcing and our team of formulation, analytical and manufacturing experts work with you to overcome challenges and identify opportunities to do more, faster. As the inventors of the KinetiSol™ Technology - a next generation amorphous solid dispersion (ASD) technology for poorly soluble APIs - we look to disrupt the ASD industry with its smaller footprint, broader design space, and greener processing solution.

Industry

Pharmaceutical Manufacturing

Company size

51-200 employees

Headquarters

Georgetown, TX

Type

Privately Held

Founded

2007

Specialties

KinetiSol™, Solid state charactarization, Amorphous solid dispersions, Solubility enhancement, CDMO, Oral Dose Forms, Pharmaceutics, and Manufacturing

Locations

Employees at AustinPx

Updates

AustinPx is excited to announce an upcoming webinar on October 1st at 1pm EDT, focusing on overcoming the challenges of scaling up Amorphous Solid Dispersions (ASDs). Join Justin Keen, Senior VP of Operations at AustinPx, and TJ Higley, CEO at Microsize, as they share best practices for tech transfer and explore improvements in scalability using next-generation technologies like KinetiSol™. The session will also cover common challenges, including feed rate variability, particle size control, and material sustainability. If you're looking to optimize your ASD development and tackle scale-up challenges, this webinar is for you! Reserve your spot now and gain valuable insights from industry experts: https://lnkd.in/gPi8UTti. #PharmaInnovation #KinetiSol #ASD #TechTransfer #PharmaManufacturing #SustainableTech #DrugDevelopment
Meet Sofia Figueroa, a dedicated scientist on our Pharmaceutics team helping to advance our client's programs to the clinic. Sofia specializes in developing amorphous solid dispersions and uses advanced techniques like dissolution, DSC, and HPLC to ensure each formulation is optimized. The work that she does is key to solving complex challenges and driving data-driven decisions for our clients. Sofia thrives in the dynamic environment of the lab, where no two days are the same. She values the opportunity to experiment with new ideas and appreciates the fast pace that keeps her continually learning and growing. She notes that her "commitment to making a positive impact through groundbreaking technology motivates her every step of the way". Discover how Sofia’s expertise is shaping the future of pharmaceutics: https://lnkd.in/gyrVRcPY. #EmployeeSpotlight #AmorphousDispersions #Pharma #Innovation #ASD
Happy Zero Emissions Day! At AustinPx we’re proud to help our clients on their sustainability journey, supporting efforts to reduce their carbon footprint and drive innovation in pharmaceutical development. In just two years, we’ve had the privilege of working with more than 30 clients to explore more sustainable amorphous dispersion development programs, helping them potentially eliminate thousands of metric tons of solvent from their supply chain each year. Let’s keep pushing boundaries and build a more sustainable future, one molecule at a time. #Sustainability #PharmaceuticalDevelopment #KinetiSol #Innovation #SolventFree #CDMO #GreenPharma
AustinPx is excited to announce an upcoming webinar on October 1st at 1pm EDT, focusing on overcoming the challenges of scaling up Amorphous Solid Dispersions (ASDs). Join Justin Keen, Senior VP of Operations at AustinPx, and TJ Higley, CEO at Microsize, as they share best practices for tech transfer and explore improvements in scalability using next-generation technologies like KinetiSol™. The session will also cover common challenges, including feed rate variability, particle size control, and material sustainability. If you're looking to optimize your ASD development and tackle scale-up challenges, this webinar is for you! Reserve your spot now and gain valuable insights from industry experts: https://lnkd.in/gPi8UTti. #PharmaInnovation #KinetiSol #ASD #TechTransfer #PharmaManufacturing #SustainableTech #DrugDevelopment
A recent survey from our colleagues at Cytiva and the Financial Times found that while sustainability is integral to success, some pharma companies are having a hard time achieving their green initiatives. Let’s explore this topic further. As our team members and partners already know, advancing sustainability within the industry is a core tenet of AustinPx and a personal passion among our leadership. Among more than 800 biopharma executives surveyed, more than half of the participating companies have experienced large boosts in brand reputation, profit, share price, revenue, and ability to attract talent, all because of their effort to practice sustainability. The survey concluded that companies must continue to place sustainability at the top of their agenda and then communicate this initiative internally and externally. At AustinPx, we want to continue this important conversation by demonstrating how sustainability drives value and innovation across the industry. For our team, KinetiSol’s superior performance to spray drying in manufacturing amorphous dispersions demonstrates how a greener, innovative alternative can not only minimize hazardous waste and emissions, but also significantly reduces timelines and total costs. Read about the survey results here: https://lnkd.in/guhFX7jm #amorphousdispersion #SustainablePharma #InnovationForChange #KinetiSol
Sustainability is increasingly important in pharma, but several hurdles are slowing the effort: survey fiercepharma.com
We are excited to share that AustinPx's Chief Technology Officer, Chris Brough, has published a new article, "Less Mess, Less Stress, Best Expressed: A Superior Alternative to Spray Drying." In the article, Brough explores how KinetiSol™ outperforms spray drying across key metrics, including bioavailability, manufacturing efficiency, and environmental impact. Unlike spray drying, KinetiSol™ eliminates the need for organic solvents, reduces the risk of drug-polymer phase separation, and enables more complex formulations with fewer processing steps, making it a game-changer for amorphous solid dispersions. Read more to learn why KinetiSol™ is setting a new standard in pharmaceutical manufacturing at www.austinpx.com/articles! #PharmaInnovation #KinetiSol #AmorphousSolidDispersions #CDMO #SustainableTech #Bioavailability

Join now to see what you are missing

Join now

AustinPx | LinkedIn (original) (raw)

Pharmaceutical Manufacturing

Georgetown, TX 2,862 followers

Client-Centric CDMO helping developers realize the full potential of their drug candidates.

About us

Locations

Employees at AustinPx

Updates

Join now to see what you are missing

Similar pages

Browse jobs